Your session is about to expire
← Back to Search
ELECTRA Trial Summary
This trial is testing a new combination drug treatment for breast cancer that has spread to the brain. It is open to men and women with this type of breast cancer.
- Brain Tumor
- Breast Disease
- Breast Cancer
- Brain Diseases
- Central Nervous System Disorders
ELECTRA Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
ELECTRA Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
ELECTRA Trial Design
Find a Location
Who is running the clinical trial?
- Your organs are not functioning properly and you are in a critical condition.You have received treatment with elacestrant or other experimental drugs that work in a similar way.
- Group 1: Phase 1b Cohort 1
- Group 2: Phase 1b Cohort 2
- Group 3: Phase 1b Cohort 3
- Group 4: Phase 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still places available in this study for participants?
"Yes, if you visit clinicaltrials.gov you will see that this study is still looking for 106 patients at 1 location. The trial was first posted on 8/31/2022 and the most recent update was on 9/7/2022."
What are the primary goals of this clinical trial?
"The primary outcome of this clinical trial, which will be measured over a 1 year time frame is to assess the efficacy of the drug combination of abemaciclib and elacestrant. Secondary outcomes include intracranial response rate per blinded independent central review (RECIST 1.1), intracranial response rate per blinded independent central review (RANO), and duration of progression free survival."
How many test subjects are involved in this research?
"That is correct. The information available on clinicaltrials.gov indicates that the recruitment period for this trial is still open. This study was first announced on 8/31/2022 and has since been updated on 9/7/2022. They are looking to 106 individuals across 1 medical facility."
Share this study with friends